ADEF
RNTX

ABS Direct Equity Fund’s Rein Therapeutics RNTX Stock Holding History

ABS Direct Equity Fund’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$163K Hold
125,000
– – 0.12% 93
2025
Q4 		$145K Buy
+125,000
New +$172K 0.17% 35

Other funds holding RNTX

VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

ABS Direct Equity Fund's RNTX Position: Q1 2026 in Review

ABS Direct Equity Fund held its Rein Therapeutics (RNTX) position steady in Q1 2026 at 125,000 shares worth $163K. The position accounts for 0.12% of the portfolio, ranked #93.

ABS Direct Equity Fund first reported a position in RNTX in Q4 2025 and has held it in 2 quarters since. 46 funds tracked by Wall St. Rank hold RNTX as of Q1 2026.

  • ABS Direct Equity Fund held 125,000 shares of Rein Therapeutics worth $163K as of Q1 2026.
  • ABS Direct Equity Fund left its Rein Therapeutics share count unchanged in Q1 2026.
  • Rein Therapeutics made up 0.12% of ABS Direct Equity Fund's portfolio in Q1 2026, its #93 holding.
  • ABS Direct Equity Fund first reported a position in Rein Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 46 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2026.

Based on ABS Direct Equity Fund's 13F filing for Q1 2026, filed 15 May 2026.